Dr. Bartlett’s Achievements
Dr. David Bartlett practices as a surgical oncologist and serves as Chair at the Allegheny Health Network (AHN) Cancer Institute. He is credited with pioneering hyperthermic intraperitoneal chemotherapy, also known as hyperthermic intraperitoneal chemoperfusion (HIPEC) for the treatment of abdominal malignancies such as malignant peritoneal mesothelioma.
Unlike systemic chemotherapy, HIPEC targets tumors directly, which helps to make it more effective and have less side effects. It is paired with cytoreduction, surgical removal of all visible tumors within the abdominal cavity. Then, HIPEC is delivered, bathing the abdominal cavity in chemotherapy for about 90 minutes to help kill any residual cancer cells.
Dr. David Bartlett is credited with pioneering hyperthermic intraperitoneal chemotherapy, also known as hyperthermic intraperitoneal chemoperfusion (HIPEC) for the treatment of abdominal malignancies such as malignant peritoneal mesothelioma.
Research
Dr. Bartlett also serves as Senior Investigator for the Division of Surgery of the Center for Cancer Research at the National Cancer Institute. He studies noval surgical techniques and viral immunotherapy for the treatment of abdominal malignancies. He has compiled the findings of his research into more than 300 peer-reviewed journal articles. He continues to advance the field of asbestos-related cancer treatment through his efforts.
When facing a diagnosis of an asbestos-related abdominal malignancy, it is crucial to find the right treatment right away. With Dr. David Bartlett, you are in good hands. Contact Dr. Bartlett today.
Rae Steinbach
Lauren Weinand